Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns

Executive Summary

Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents

You may also be interested in...



Norvir Generics Are Years Away, Even If NIH Exercises “March-In” Rights

Generic versions of Abbott's protease inhibitor Norvir (ritonavir) would still face patent litigation, even if the National Institutes of Health decides to "march in" on the patents for the drug

Norvir Generics Are Years Away, Even If NIH Exercises “March-In” Rights

Generic versions of Abbott's protease inhibitor Norvir (ritonavir) would still face patent litigation, even if the National Institutes of Health decides to "march in" on the patents for the drug

Abbott Norvir Compulsory Licensing Will Be Debated By NIH

An NIH public hearing on Abbott's Norvir will address whether the federal government should use "march-in" authorities to grant compulsory licensing of Norvir patents

Related Content

UsernamePublicRestriction

Register

PS044076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel